Akari Therapeutics (AKTX) vs Aytu BioPharma (AYTU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aytu BioPharma (AYTU) has outperformed Akari Therapeutics (AKTX) over the past year, losing 13.5% versus a loss of 80.1%. Over five years, AYTU leads with a -96.1% price change compared with -99.4% for AKTX. Aytu BioPharma is the larger company by market cap ($22.0 million vs $19.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTX | AYTU |
|---|---|---|
| Share price | $8.67 | $2.02 |
| Market cap | $19.81M | $21.95M |
| 1-day change | +2.12% | -1.46% |
| YTD return | -29.67% | -21.15% |
| 1-year return | -80.07% | -13.50% |
| 5-year return | -99.38% | -96.13% |
| Forward P/E | — | 13.03 |
| EPS (TTM) | $0.00 | $-1.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.00 | $3.07 |
| 52-week low | $3.02 | $1.80 |
| Distance from 52-week high | -78.33% | -34.20% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +194.12% | +378.71% |
| Average volume | 61.08K | 34.22K |
| Shares outstanding | 2.29M | 10.87M |
| Employees | 5 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AYTU has outperformed AKTX by 66.6 percentage points over the past year.
About Akari Therapeutics
AKTX stock →Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Aytu BioPharma
AYTU stock →Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
AKTX vs AYTU FAQ
Which is bigger, Akari Therapeutics or Aytu BioPharma?
Aytu BioPharma (AYTU) is larger, with a market capitalization of $21.95M compared with $19.81M for Akari Therapeutics (AKTX).
Which stock has performed better over the past year, AKTX or AYTU?
AYTU returned -13.50% over the past 12 months, compared with -80.07% for AKTX (price return, excluding dividends). Past performance does not predict future results.
Are Akari Therapeutics and Aytu BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.